Secora Michael
Insider CIK 1855980 · RXRX Chief Financial Officer · IAM CFO & Chief Corp Dev Ofcr
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| IAM Iambic Therapeutics, Inc. | C Conversion deriv | 2026-10-16 | 2026-10-19 | 61,342 | — | $0 | 0 | SEC↗ |
| IAM Iambic Therapeutics, Inc. | C Conversion | 2026-10-16 | 2026-10-19 | 61,342 | — | — | 279,902 | SEC↗ |
| IAM Iambic Therapeutics, Inc. | A Award deriv | 2026-10-14 | 2026-10-16 | 170,300 | — | $0 | 170,300 | SEC↗ |
| IAM Iambic Therapeutics, Inc. | A Award | 2026-10-14 | 2026-10-16 | 28,400 | — | $0 | 218,560 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2024-11-15 | 2024-11-19 | 11,937 | $6.18 | $73.8K | 1,487,694 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-11-13 | 2024-11-14 | 39,375 | — | $0 | 337,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-11-13 | 2024-11-14 | 39,375 | $2.22 | $87.4K | 1,514,631 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-11-13 | 2024-11-14 | 15,000 | $7.66 | $114.9K | 1,499,631 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-11-12 | 2024-11-14 | 39,375 | — | $0 | 377,010 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-11-12 | 2024-11-14 | 15,000 | $7.64 | $114.6K | 1,475,256 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-11-12 | 2024-11-14 | 39,375 | $2.22 | $87.4K | 1,490,256 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-10-09 | 2024-10-10 | 39,375 | — | $0 | 416,385 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-10-09 | 2024-10-10 | 15,000 | $6.36 | $95.4K | 1,450,881 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-10-09 | 2024-10-10 | 39,375 | $2.22 | $87.4K | 1,465,881 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-10-08 | 2024-10-10 | 39,375 | — | $0 | 455,760 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-10-08 | 2024-10-10 | 15,000 | $6.32 | $94.8K | 1,426,506 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-10-08 | 2024-10-10 | 39,375 | $2.22 | $87.4K | 1,441,506 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-09-11 | 2024-09-12 | 39,375 | — | $0 | 495,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-09-11 | 2024-09-12 | 39,375 | $2.22 | $87.4K | 1,417,131 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-09-11 | 2024-09-12 | 15,000 | $6.32 | $94.8K | 1,402,131 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-09-10 | 2024-09-12 | 39,375 | — | $0 | 534,510 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-09-10 | 2024-09-12 | 39,375 | $2.22 | $87.4K | 1,392,756 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-09-10 | 2024-09-12 | 15,000 | $6.17 | $92.5K | 1,377,756 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2024-08-15 | 2024-08-19 | 11,962 | $6.69 | $80.0K | 1,353,381 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-08-14 | 2024-08-15 | 39,375 | — | $0 | 573,885 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-08-14 | 2024-08-15 | 39,375 | $2.22 | $87.4K | 1,380,343 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-08-14 | 2024-08-15 | 15,000 | $6.35 | $95.3K | 1,365,343 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-08-13 | 2024-08-15 | 39,375 | — | $0 | 613,260 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-08-13 | 2024-08-15 | 15,000 | $6.35 | $95.3K | 1,340,968 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-08-13 | 2024-08-15 | 39,375 | $2.22 | $87.4K | 1,355,968 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-07-10 | 2024-07-11 | 39,375 | — | $0 | 652,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-07-10 | 2024-07-11 | 15,000 | $7.24 | $108.6K | 1,316,593 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-07-10 | 2024-07-11 | 39,375 | $2.22 | $87.4K | 1,331,593 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-07-09 | 2024-07-11 | 39,375 | — | $0 | 692,010 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-07-09 | 2024-07-11 | 15,000 | $7.32 | $109.8K | 1,292,218 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-07-09 | 2024-07-11 | 39,375 | $2.22 | $87.4K | 1,307,218 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-06-14 | 2024-06-17 | 39,375 | — | $0 | 731,385 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-06-14 | 2024-06-17 | 39,375 | $2.22 | $87.4K | 1,282,843 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-06-14 | 2024-06-17 | 15,000 | $9.27 | $139.1K | 1,267,843 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-06-13 | 2024-06-17 | 39,375 | — | $0 | 770,760 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-06-13 | 2024-06-17 | 39,375 | $2.22 | $87.4K | 1,258,468 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-06-13 | 2024-06-17 | 15,000 | $9.32 | $139.8K | 1,243,468 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2024-05-15 | 2024-05-17 | 11,962 | $10.01 | $119.7K | 1,219,093 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-04-17 | 2024-04-18 | 37,500 | — | $0 | 810,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-04-17 | 2024-04-18 | 37,500 | $2.22 | $83.3K | 1,254,179 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-04-17 | 2024-04-18 | 23,124 | $7.58 | $175.3K | 1,231,055 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-04-16 | 2024-04-18 | 37,500 | — | $0 | 847,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-04-16 | 2024-04-18 | 37,500 | $2.22 | $83.3K | 1,241,679 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-04-16 | 2024-04-18 | 25,000 | $7.67 | $191.8K | 1,216,679 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-03-13 | 2024-03-14 | 37,500 | — | $0 | 885,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-03-13 | 2024-03-14 | 37,500 | $2.22 | $83.3K | 1,229,179 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-03-13 | 2024-03-14 | 25,000 | $11.03 | $275.8K | 1,204,179 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-03-12 | 2024-03-14 | 37,500 | — | $0 | 922,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-03-12 | 2024-03-14 | 37,500 | $2.22 | $83.3K | 1,216,679 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-03-12 | 2024-03-14 | 25,000 | $10.46 | $261.5K | 1,191,679 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2024-02-15 | 2024-02-16 | 7,172 | $12.43 | $89.1K | 1,179,179 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-02-14 | 2024-02-15 | 37,500 | — | $0 | 960,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-02-14 | 2024-02-15 | 1,067 | $10.98 | $11.7K | 1,186,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-02-14 | 2024-02-15 | 23,933 | $10.43 | $249.6K | 1,187,418 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-02-14 | 2024-02-15 | 37,500 | $2.22 | $83.3K | 1,211,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-02-13 | 2024-02-15 | 37,500 | — | $0 | 997,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-02-13 | 2024-02-15 | 37,500 | $2.22 | $83.3K | 1,198,851 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-02-13 | 2024-02-15 | 25,000 | $9.86 | $246.5K | 1,173,851 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2024-02-09 | 2024-02-13 | 348,380 | — | $0 | 348,380 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2024-02-09 | 2024-02-13 | 8,659 | — | $0 | 989,673 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2024-02-09 | 2024-02-13 | 174,190 | — | $0 | 1,163,863 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2024-02-09 | 2024-02-13 | 2,512 | $10.09 | $25.3K | 1,161,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-01-17 | 2024-01-18 | 37,500 | — | $0 | 1,035,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-01-17 | 2024-01-18 | 25,000 | $10.25 | $256.3K | 981,014 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-01-17 | 2024-01-18 | 37,500 | $2.22 | $83.3K | 1,006,014 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-01-16 | 2024-01-18 | 37,500 | — | $0 | 1,072,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-01-16 | 2024-01-18 | 25,000 | $10.45 | $261.2K | 968,514 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-01-16 | 2024-01-18 | 37,500 | $2.22 | $83.3K | 993,514 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-12-13 | 2023-12-14 | 37,500 | — | $0 | 1,110,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-12-13 | 2023-12-14 | 37,500 | $2.22 | $83.3K | 981,014 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-12-13 | 2023-12-14 | 25,000 | $7.59 | $189.8K | 956,014 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-12-12 | 2023-12-14 | 37,500 | — | $0 | 1,147,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-12-12 | 2023-12-14 | 25,000 | $7.39 | $184.8K | 943,514 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-12-12 | 2023-12-14 | 37,500 | $2.22 | $83.3K | 968,514 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-11-15 | 2023-11-16 | 37,500 | — | $0 | 1,185,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-11-15 | 2023-11-16 | 37,500 | $2.22 | $83.3K | 963,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-11-15 | 2023-11-16 | 4,700 | $7.62 | $35.8K | 938,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-11-15 | 2023-11-16 | 20,300 | $7.25 | $147.2K | 942,886 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-11-15 | 2023-11-16 | 7,172 | $7.18 | $51.5K | 931,014 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-11-14 | 2023-11-16 | 37,500 | — | $0 | 1,222,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-11-14 | 2023-11-16 | 25,000 | $6.32 | $158.0K | 925,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-11-14 | 2023-11-16 | 37,500 | $2.22 | $83.3K | 950,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-10-11 | 2023-10-12 | 37,500 | — | $0 | 1,260,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-10-11 | 2023-10-12 | 37,500 | $2.22 | $83.3K | 938,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-10-11 | 2023-10-12 | 25,000 | $6.85 | $171.3K | 913,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-10-10 | 2023-10-12 | 37,500 | — | $0 | 1,297,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-10-10 | 2023-10-12 | 25,000 | $7.07 | $176.8K | 900,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-10-10 | 2023-10-12 | 37,500 | $2.22 | $83.3K | 925,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-09-13 | 2023-09-14 | 37,500 | — | $0 | 1,335,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-09-13 | 2023-09-14 | 25,000 | $8.69 | $217.3K | 888,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-09-13 | 2023-09-14 | 37,500 | $2.22 | $83.3K | 913,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-09-12 | 2023-09-14 | 37,500 | — | $0 | 1,372,635 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-09-12 | 2023-09-14 | 25,000 | $8.43 | $210.8K | 875,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-09-12 | 2023-09-14 | 37,500 | $2.22 | $83.3K | 900,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-08-16 | 2023-08-17 | 37,500 | — | $0 | 1,410,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-08-16 | 2023-08-17 | 25,000 | $8.90 | $222.5K | 863,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-08-16 | 2023-08-17 | 37,500 | $2.22 | $83.3K | 888,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-08-15 | 2023-08-17 | 37,500 | — | $0 | 1,485,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-08-15 | 2023-08-17 | 4,727 | $9.19 | $43.4K | 838,186 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-08-15 | 2023-08-17 | 37,500 | $2.22 | $83.3K | 875,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-08-15 | 2023-08-17 | 25,000 | $9.27 | $231.8K | 850,686 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-19 | 2023-07-19 | 37,500 | — | $0 | 670,313 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-19 | 2023-07-19 | 9,859 | $16.00 | $157.7K | 842,913 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-19 | 2023-07-19 | 13,150 | $15.36 | $202.0K | 852,772 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-19 | 2023-07-19 | 1,991 | $14.36 | $28.6K | 865,922 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-19 | 2023-07-19 | 37,500 | $2.22 | $83.3K | 867,913 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-18 | 2023-07-19 | 37,500 | — | $0 | 707,813 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-18 | 2023-07-19 | 37,500 | $2.22 | $83.3K | 855,413 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-18 | 2023-07-19 | 24,500 | $13.62 | $333.7K | 830,913 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-18 | 2023-07-19 | 500 | $14.05 | $7.0K | 830,413 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-06-14 | 2023-06-15 | 37,500 | — | $0 | 745,313 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-06-14 | 2023-06-15 | 37,500 | $2.22 | $83.3K | 842,913 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-14 | 2023-06-15 | 25,000 | $10.07 | $251.8K | 817,913 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-06-13 | 2023-06-15 | 37,500 | — | $0 | 782,813 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-13 | 2023-06-15 | 25,000 | $9.93 | $248.3K | 805,413 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-06-13 | 2023-06-15 | 37,500 | $2.22 | $83.3K | 830,413 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-05-15 | 2023-05-17 | 4,760 | $5.60 | $26.7K | 790,159 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-02-15 | 2023-02-17 | 1,258 | $8.44 | $10.6K | 794,310 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2023-02-01 | 2023-02-03 | 404,857 | — | $0 | 404,857 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-02-01 | 2023-02-03 | 202,428 | — | $0 | 790,502 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-02-01 | 2023-02-03 | 2,669 | $8.55 | $22.8K | 795,568 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-02-01 | 2023-02-03 | 7,735 | — | $0 | 798,237 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-11-15 | 2022-11-17 | 1,065 | $11.86 | $12.6K | 586,572 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-08-15 | 2022-08-17 | 1,065 | $12.96 | $13.8K | 587,637 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-05-16 | 2022-05-18 | 1,069 | $5.67 | $6.1K | 588,702 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2023-04-28 | 1,957 | — | $0 | 591,058 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2023-04-28 | 58,342 | — | $0 | 589,101 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-02-04 | 2023-04-28 | 678 | $11.40 | $7.7K | 590,380 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2022-02-04 | 2022-02-08 | 116,684 | — | $0 | 116,684 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2022-02-04 | 2022-02-08 | 3,914 | — | $0 | 3,914 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2022-02-08 | 1,957 | — | $0 | 590,449 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-02-04 | 2022-02-08 | 678 | $11.40 | $7.7K | 589,771 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2022-02-08 | 58,342 | — | $0 | 588,492 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 820,313 | — | $0 | 820,313 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 820,313 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 1,500,000 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 1,500,000 | — | $0 | 1,500,000 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 149,077 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 528,762 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 528,762 | — | $0 | 528,762 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion | 2021-04-20 | 2021-04-22 | 149,077 | — | $0 | 528,762 | SEC↗ |